Navigation Links
MGT Capital Investments, Inc.'s Plan of Compliance Accepted by NYSE AMEX, LLC
Date:8/29/2011

NEW YORK, Aug. 29, 2011 /PRNewswire/ -- MGT Capital Investments, Inc. ("MGT", "we", or "the Company") (AMEX: MGT.BC), a holding company engaged in the medical imaging industry, announced today that NYSE Amex, LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") submitted in response to a notice from the Exchange Staff dated June 8, 2011 indicating that the Company was not in compliance with certain continued listing standards as set forth in Part 10 of the Exchange's Company Guide.

Specifically, the Exchange Staff noted that the Company was not in compliance with: (a) Section 1003(a)(i) of the Company Guide, resulting from stockholders' equity on March 31, 2011 of less than $2,000,000 and losses from continuing operations and/or net losses in two of its three most recent fiscal years; (b) Section 1003(a)(ii) of the Company Guide with stockholders' equity of less than $4,000,000 and losses from continuing operations and/or net losses in three of its four most recent fiscal years; and (c) Section 1003(a)(iii) with stockholders' equity of less than $6,000,000 and losses from continuing operations and/or net losses in its five most recent fiscal years.  The Company was afforded the opportunity to submit the Plan to the Exchange and on July 15, 2011 presented the Plan to the Exchange.  

On August 23, 2011, the Exchange notified the Company that it had accepted the Plan and granted the Company an extension until December 8, 2012 to regain compliance with Sections 1003(a) (i)-(iii) of the Company Guide.  The Company will be subject to periodic review by Exchange Staff during the extension period.  Failure to make progress consistent with the Plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Exchange initiating delisting proceedings pursuant to Section 1009 of the Company Guide.

The Exchange further notified the Company that its common stock had fallen to a low trading price for a significant period of time and that the Company was therefore not in compliance with Section 1003(f)(v) of the Company Guide.  The Company was given until February 23, 2012 to comply with this Section.  The Exchange noted that MGT could regain compliance by effectuating a reverse-split of its common stock prior to February 23, 2012.  The Company intends to use its best efforts to utilize this remedy.

MGT's common stock continues to trade on the Exchange under the symbol MGT.BC. The trading symbol will bear this additional "B.C." indicator until the Company regains its compliance with the Exchange's continued listing requirements.

About MGT Capital Investments, Inc.

MGT is a holding company comprised of MGT, the parent company, and its wholly-owned subsidiaries:  MGT Capital Investments (U.K.) Limited, MGT Investments (Gibraltar) Limited, and Medicsight Nominees Limited.  In addition we also have a controlling interest in our operating subsidiary, Medicsight PLC, including its wholly owned subsidiaries.  

Medicsight is a medical technology company focusing on medical imaging software development and medical hardware devices. Medicsight is listed on the AIM Market of the London Stock Exchange under the ticker symbol "MDST."  The company provides Computer-Aided Detection ("CAD") applications to analyze Computer Tomography ("CT") scans in order to assist radiologists with early detection and measurement of colorectal polyps.  The CAD software received a CE Mark in 2009, which allows for sales in the European Union; In May of 2011, MDST's software also received clearance from the U. S. FDA.  Revenue is presently limited as MDST attempts to commercialize its recent U.S. approval.  MDST has also developed an automated carbon dioxide medical inflation device and associated disposable tubing (MedicCO 2 LON) that is being commercialized in partnership with a global distributor.

On June 30, 2011, MGT held 83.75 million shares (53.85%) of the 155.5 million issued share capital of MDST.

Contact:

MGT Capital Investments, Inc.

Robert Ladd, Interim Chief Executive Officer
rladd@mgtci.com

Robert Traversa, Chief Financial Officer
rtraversa@mgtci.com


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Corporation Announces Receipt of Requisite Consents, Termination of Replacement Capital Covenant and Expiration of Consent Solicitation Relating to its 6.125% Senior Notes due August 15, 2016 (CUSIP NO. 126650BE9)
2. MGT Capital Investments, Inc. Provides Update on Recent Developments
3. KPS Capital Partners to Sell Attends Healthcare, Inc. to Domtar Corporation for $315 Million
4. Vycor Medical, Inc. Completes Final Close on Equity Capital Raise
5. HASCO Medical Chairman Provides $2 Million in Capital and a Personal Guarantee on Additional $2 Million Promissory Note
6. Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimers Disease Using a Drop of Blood
7. Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
8. CSA Medical Completes $12.6 Million Series A Financing With Additional Venture Investment From Blue Heron Capital
9. ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions
10. Boston Scientific to Donate $1 Million to ASGEs IT & T Capital Campaign to Build a New State-of-the-Art GI Training Center
11. SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):